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HepatotoxicityAbstract A series of 3-diphenylmethyl-6-substituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole deriva-
tives (4a–j and 5a–d) were synthesized by condensation of 4-amino-5-diphenylmethyl-4H-1,2,4-tri-
azole-3-thiol with various substituted aromatic acids and aryl/alkyl-isothiocyanates. The structures
of synthesized compounds were characterized by elemental analysis, IR, 1H NMR, 13C NMR and
mass spectroscopic studies. These compounds were tested in vivo for their anti-inﬂammatory activ-
ity. The compounds which showed activity comparable to the standard drug ibuprofen were
screened for their analgesic, ulcerogenic, lipid peroxidation and hepatotoxic effects. Compounds
6-(4-chlorophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (4a) and 6-(2,4-dichlo-
rophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole(4c) emerged as the most active
compounds of the series and were moderately more potent than the standard drug ibuprofen.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are widely
used to treat sign and symptoms of inﬂammation, particularly
arthritic pain. NSAIDs exert their anti-inﬂammatory effects
mainly through inhibition of cyclooxygenase (COX) enzymes,
thus preventing prostaglandin biosynthesis from arachidonic
acid which is also responsible for their main undesirable side
effects (Warner et al., 1999). The chronic use of non selective
NSAIDs results in gastrointestinal irritation, bleeding and for-
mation of life threatening gastrointestinal ulcers (Allison et al.,
956 M.W. Akhter et al.1992). Later on, selective NSAID agents (coxibs) were devel-
oped as new generation drugs, free from GI toxicity (Tally
et al., 2000), but unfortunately coxibs were found to have
adverse cardiovascular effects (Dogne et al., 2005). Therefore
the search for novel compounds having anti-inﬂammatory
and analgesic activity with improved safety proﬁle is still a
necessity.
Heterocyclic compounds bearing symmetrical 1,2,4-triazole
or 1,3,4-thiadiazole moieties have been reported possessing a
broad spectrum of pharmacological properties including
potential anti-inﬂammatory and analgesic activities
(Schenone et al., 2006; Tozkoparan et al., 2007). Moreover,
the chemistry of 1,2,4-triazoles and their fused heterocyclic
derivatives has received considerable attention owing to their
synthetic and effective biological importance (Swamy et al.,
2006; Karthikeyan et al., 2007; Karegouder et al., 2008). For
example derivatives of 1,2,4-triazole and 1,3,4-thiadiazole con-
densed nucleus systems (triazolothiadiazole) were found to
have diverse pharmacological properties (Mathew et al.,
2006, 2009). Furthermore, literature survey revealed that mod-
iﬁcation of carboxyl function of various aryl alkanoic acids
resulted in increased anti-inﬂammatory activity with reduced
ulcerogenic effects (Kalgutkar et al., 2000; Kucukguzel et al.,
2007). Our earlier studies (Amir and Kumar, 2004, 2005) have
shown that certain compounds bearing 1,2,4-triazole and
1,3,4-thiadiazole nuclei possess signiﬁcant anti-inﬂammatory
activities with reduced GI toxicity. Furthermore, several triaz-
olothiadiazole derivatives have been prepared from different
nonsteroidal anti-inﬂammatory agents and were found to pos-
sess improved pharmacological proﬁles (Metwally et al., 2007).
Encouraged by these observations and in continuation of our
research program on the synthesis of heterocyclic compounds
of arylalkanoic acids (Amir et al., 2007, 2008), we report herein
the synthesis of some new triazolothiadiazole derivatives of
diphenylacetic acid. The synthesized compounds have been
found to possess an interesting proﬁle of anti-inﬂammatory
and analgesic activities with signiﬁcant reduction in the ulcero-
genic effect.2. Experimental
2.1. Chemistry
The entire chemical reagents which are used in the study are
procured from E. Merck (Germany) and S.D. Fine Chemicals
(India). The completion of reaction is monitored by thin layer
chromatography (TLC) using chloroform–methanol (9:1) as
the solvent system. The products were puriﬁed by recrystallisa-
tion with absolute ethanol and purity of the compounds was
checked by thin layer chromatography (TLC) using silica gel
G plates (Merck). The spot was developed in iodine chamber
or viewed under UV lamp. Melting points were determined
in an open capillary using melting point apparatus and are
uncorrected. The proton magnetic resonance (1H NMR) spec-
tra were recorded on a Bruker 300 MHz instrument in DMSO
d6 using tetramethylsilane as an internal standard. The infrared
spectra of compounds were recorded in KBr on a Bio-Rad
FTIR spectrophotometer. Diphenyl acetic acid hydrazide (1)
was prepared by the procedure given in the literature
(Metwally et al., 2007).2.2. Synthesis of potassium dithiocarbazinate (2)
To a solution of diphenyl acetic acid hydrazide 1 (0.02 mol) in
absolute ethanol (50 mL) and KOH (0.03 mol), carbon disul-
ﬁde (0.025 mol) was added in small portions with constant stir-
ring. The reaction mixture was agitated continuously for 12 h
at room temperature. The precipitated potassium dithiocar-
bazinate was collected by ﬁltration, washed with anhydrous
ether (100 mL) and dried in vacuum. The potassium salt was
thus obtained in quantitative yield and was used in the next
step without further puriﬁcation.
2.3. Synthesis of 4-amino-5-diphenylmethyl-4H-1,2,4-triazole-3-
thiol (3)
A solution of potassium dithiocarbazinate (2) (0.02 mol) and
hydrazine hydrate (99%, 0.04 mol) in water (10 mL) was
reﬂuxed for 15 h with occasional shaking. The color of the
reaction mixture turned green as the evolution of H2S gas
ceased. The reaction mixture was cooled, diluted with water
(20 mL) and acidiﬁed with acetic acid. The precipitate
obtained was ﬁltered, washed, dried and recrystallized from
ethanol.
Yield: 71%, m.p.: 198 C. IR (KBr, cm1): 3293 (NH), 2890
(CH), 2532 (SH), 1610 (C‚N); 1H NMR (CDCl3) d (ppm):
5.42 (s, 1H, NH2), 5.68 (s, 1H, CH), 7.15–7.26 (m, 10H,
ArH), 13.62 (s, 1H, SH); MS (m/z): 282 (M+). Anal. Calcd
for C15H14N4S: C, 63.80; H, 5.00; N, 19.84; Found: C, 63.61;
H, 5.12; N, 19.71%.
2.4. General procedure for synthesis of 3-diphenylmethyl-6-
(substituted)-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles (4a–j)
An equimolar mixture of 4-amino-5-diphenylmethyl-4H-1,2,
4-triazole-3-thiol (3) (0.01 mol) and aromatic acids (0.01 mol)
in phosphorus oxychloride (10 mL) was reﬂuxed for 3–5 h.
The reaction mixtures were cooled to room temperature and
then gradually poured on to crushed ice with stirring. The mix-
tures were allowed to stand overnight and the solids separated
out were ﬁltered, treated with dilute sodium hydroxide solu-
tion and washed thoroughly with cold water. The compound
so obtained was dried and recrystallized with ethanol.
2.4.1. 6-(4-Chlorophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4a)
Yield: 74%; m.p.: 238 C. IR (KBr, cm1): 2912 (CH), 1622
(C‚N), 698 (CASAC); 1H NMR (CDCl3) d (ppm): 5.96 (s,
1H, CH), 7.16–7.37 (m, 10H, ArH), 7.40 (d, 2H, J= 8.4 Hz,
ArH), 7.66 (d, 2H, J= 8.4 Hz, ArH); 13C NMR (CDCl3) d
(ppm): 48.18 (CH), 127.31 (2CHarom), 127.89 (CHarom),
128.32 (2CHarom), 128.62 (4CHarom), 128.81 (4CHarom),
129.74 (2CHarom), 131.36 (CHarom), 139.0 (2CHarom), 139.11
(CHarom), 149.12 (CHarom), 165.26 (CHarom); MS (m/z): 402
(M+), 404 (M++2). Anal. Calcd for C22H15ClN4S: C,
65.58; H, 3.75; N, 13.91; Found: C, 65.39; H, 3.58; N, 13.98%.
2.4.2. 6-(2-Chlorophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4b)
Yield: 69%; m.p.: 145 C. IR (KBr, cm1): 2943 (CH), 1631
(C‚N), 701 (CASAC); 1H NMR (CDCl3) d (ppm): 5.93 (s,
Synthesis of 3-diphenylmethyl-6-substituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles 9571H, CH), 7.21–7.41 (m, 10H, ArH), 7.47 (d, 2H, J= 7.8 Hz,
ArH), 7.64 (d, 2H, J= 8.1 Hz, ArH); 13C NMR (CDCl3) d
(ppm): 48.28 (CH), 126.34 (2CHarom), 127.79 (CHarom),
128.39 (2CHarom), 129.12 (4CHarom), 129.53 (4CHarom),
129.94 (2CHarom), 132.30 (CHarom), 139.56 (2CHarom), 139.91
(CHarom), 148.93 (CHarom), 164.16 (CHarom); MS (m/z): 402
(M+), 404 (M++2). Anal. Calcd for C22H15ClN4S: C,
65.58; H, 3.75; N, 13.91; Found: C, 65.34; H, 3.53; N, 13.73%.
2.4.3. 6-(2,4-Dichlorophenyl)-3-diphenylmethyl-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole (4c)
Yield: 68%; m.p.: 172 C. IR (KBr, cm1): 2945 (CH), 1653
(C‚N), 708 (CASAC); 1H NMR (CDCl3) d (ppm): 6.03 (s,
1H, CH), 7.27–7.42 (m, 10H, ArH), 7.55 (d, 1H, J= 1.2 Hz,
ArH,), 7.80 (d, 2H, J= 6.3 Hz, ArH); 13C NMR (CDCl3) d
(ppm): 48.38 (CH), 126.31 (2CHarom), 127.59 (CHarom),
128.33 (4CHarom), 128.92 (4CHarom), 129.50 (2CHarom),
130.53 (CHarom), 132.90 (CHarom), 136.26 (CHarom), 137.92
(CHarom), 145.32 (2CHarom), 149.67 (CHarom), 165.26
(CHarom); MS (m/z): 436 (M
+), 438 (M++2). Anal. Calcd
for C22H14Cl2N4S: C, 60.42; H, 3.23; N, 12.81; Found: C,
60.17; H, 3.29; N, 12.61%.
2.4.4. 3-Diphenylmethyl-6-(2-methylphenyl)-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4d)
Yield: 85%, m.p.: 141 C. IR (KBr, cm1): 2964 (CH), 1653
(C‚N), 723 (CASAC); 1H NMR (CDCl3) d (ppm): 2.38 (s,
3H, CH3), 6.05 (s, 1H, CH), 7.25–7.45 (m, 14H, ArH);
13C
NMR (CDCl3) d (ppm): 21.48 (CH3), 48.38 (CH), 126.63
(3CHarom), 127.39 (CHarom), 128.13 (CHarom), 128.69
(4CHarom), 128.80 (4CHarom), 129.95 (CHarom), 131.80
(CHarom), 132.09 (2CHarom), 137.92 (CHarom), 138.76
(2CHarom), 166.67 (CHarom); MS (m/z): 382 (M
+). Anal. Calcd
for C23H18N4S: C, 72.22; H, 4.74; N, 14.65; Found: C, 72.01;
H, 4.54; N, 14.48%.
2.4.5. 6-(4-Aminophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4e)
Yield: 76%, m.p.: 153 C. IR (KBr, cm1): 2925 (CH), 1628
(C‚N), 713 (CASAC); 1H NMR (CDCl3) d (ppm): 5.54 (s,
1H, CH), 6.23 (s, 2H, NH2), 6.67 (d, 2H, J= 6 Hz, ArH),
7.29–7.47 (m, 10H, ArH), 7.56 (d, 2H, J= 6.3 Hz, ArH),
13C NMR (CDCl3) d (ppm): 48.31 (CH), 122.21 (2CHarom),
125.36 (2CHarom), 128.32 (2CHarom), 129.43 (4CHarom),
129.98 (4CHarom), 135.20 (CHarom), 135.87 (2CHarom), 137.90
(CHarom), 145.27 (CHarom), 149.43 (CHarom), 165.16 (CHarom);
MS (m/z): 383 (M+). Anal. Calcd for C22H17N5S: C, 68.91; H,
4.47; N, 18.26; Found: C, 68.59; H, 4.27; N, 18.02%.
2.4.6. 3-Diphenylmethyl-6-(4-nitrophenyl)-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4f)
Yield: 79%; m.p.: 198 C. IR (KBr, cm1): 2958 (CH), 1646
(C‚N), 697 (CASAC); 1H NMR (CDCl3) d (ppm): 6.05 (s,
1H, CH), 7.26–7.43 (m, 10H, ArH), 7.99 (d, 2H, J= 6 Hz,
ArH), 8.34 (d, 2H, J= 6.3 Hz, ArH); 13C NMR (CDCl3) d
(ppm): 48.31 (CH), 125.21 (2CHarom), 126.32 (2CHarom),
128.10 (2CHarom), 129.23 (4CHarom), 129.79 (4CHarom),
134.21 (CHarom), 135.29 (2CHarom), 138.92 (CHarom), 145.17
(CHarom), 149.23 (CHarom), 164.36 (CHarom); MS (m/z): 413(M+). Anal. Calcd for C22H15N5O2S: C, 63.91; H, 3.66; N,
16.94; Found: C, 63.75; H, 3.35; N, 16.73%.
2.4.7. 6-(2-Bromophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4g)
Yield: 65%; m.p.: 152 C. IR (KBr, cm1): 2956 (CH), 1637
(C‚N), 721 (CASAC); 1H NMR (CDCl3) d (ppm): 5.91
(s, 1H, CH), 7.23–7.39 (m, 10H, ArH), 7.41 (d, 2H,
J= 7.2 Hz, ArH), 7.66 (d, 2H, J= 7.2 Hz, ArH); 13C NMR
(CDCl3) d (ppm): 48.43 (CH), 127.46 (2CHarom), 128.43
(4CHarom), 128.92 (4CHarom), 129.86 (2CHarom), 130.74
(2CHarom), 133.36 (CHarom), 137.43 (2CHarom), 138.93
(CHarom), 139.38 (CHarom), 146.90 (CHarom), 167.26 (CHarom);
MS (m/z): 448 (M+), 450 (M++2). Anal. Calcd. for C22H15-
BrN4S: C, 59.07; H, 3.38; N, 12.52; Found: C, 59.19; H,
3.11; N, 12.32%.
2.4.8. 6-(4-Bromophenyl)-3-diphenylmethyl-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazole (4h)
Yield: 87%; m.p.: 248 C. IR (KBr, cm1): 2943 (CH), 1632
(C‚N), 698 (CASAC); 1H NMR (CDCl3) d (ppm): 6.01 (s,
1H, CH), 7.27–7.39 (m, 10H, ArH), 7.41 (d, 2H, J= 8.1 Hz,
ArH), 7.62 (d, 2H, J= 8.4 Hz, ArH); 13C NMR (CDCl3) d
(ppm): 48.12 (CH), 127.21 (2CHarom), 128.73 (4CHarom),
128.99 (4CHarom), 130.86 (2CHarom), 131.74 (2CHarom),
133.76 (CHarom), 137.78 (2CHarom), 139.71 (CHarom), 140.35
(CHarom), 145.99 (CHarom), 164.26 (CHarom); MS (m/z): 448
(M+), 450 (M++2). Anal. Calcd for C22H15BrN4S: C,
59.07; H, 3.38; N, 12.58; Found: C, 58.89; H, 3.12; N, 12.33%.
2.4.9. 6-(4-Bromo-2-chlorophenyl)-3-diphenylmethyl-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole (4i)
Yield: 78%, m.p.: 169 C. IR (KBr, cm1): 2935 (CH), 1623
(C‚N), 723 (CASAC); 1H NMR (CDCl3) d (ppm): 6.03 (s,
1H, CH), 7.25–7.42 (m, 10H, ArH), 7.55 (dd, 1H,
J= 1.2 Hz, 5.1 Hz, ArH), 7.70–7.74 (m, 2H, ArH); 13C
NMR (CDCl3) d (ppm): 48.26 (CH), 126.86 (CHarom), 126.90
(CHarom), 127.42 (2CHarom), 128.73 (4CHarom), 128.84
(4CHarom), 130.99 (CHarom), 131.92 (CHarom), 133.70
(CHarom), 133.84 (2CHarom), 139.04 (CHarom), 148.87
(CHarom), 154.33 (CHarom), 162.32 (CHarom); MS (m/z): 482
(M+), 484 (M++2). Anal. Calcd for C22H14BrClN4S: C,
54.84; H, 2.93; N, 11.63; Found: C, 54.67, H, 2.70; N, 11.45%.
2.4.10. 6-[(2,4-Dichlorophenoxy)methyl]-3-diphenylmethyl-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (4j)
Yield: 73%; m.p.: 176 C. IR (KBr, cm1): 2975 (CH), 1624
(C‚N), 718 (CASAC); 1H NMR (CDCl3) d (ppm): 5.26 (s,
2H, OCH2), 5.95 (s, 1H, CH), 6.84 (d, 1H, J= 6.6 Hz,
ArH), 7.16 (d, 1H, J= 6.3 Hz, ArH), 7.27–7.36 (m, 10H,
ArH), 7.41 (s, 1H, ArH); 13C NMR (CDCl3) d (ppm): 48.35
(CH), 73.20 (CH), 123.61 (CHarom), 126.23 (CHarom), 126.96
(2CHarom), 127.34 (CHarom), 128.31 (CHarom), 129.14
(4CHarom), 129.56 (4CHarom), 136.58 (CHarom), 137.98
(2CHarom), 139.53 (CHarom), 141.35 (CHarom), 145.21
(CHarom), 163.11 (CHarom); MS (m/z): 466 (M
+), 468
(M++2). Anal. Calcd for C23H16Cl2N4OS: C, 59.11; H,
3.45; N, 11.99; Found: C, 59.21, H, 3.17; N, 11.76%.
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(substituted amino)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
(5a–d)
An equimolar mixture of 4-amino-5-diphenylmethyl-4H-1,2,4-
triazole-3-thiol (3) (0.01 mol) and aryl/alkyl isothiocyanates
(0.01 mol) in DMF (20 mL) was reﬂuxed for 12–16 h. The
reaction mixture was cooled to room temperature and then
gradually poured on to crushed ice with stirring. The mixture
was allowed to stand overnight and the solid separated out was
ﬁltered, and washed thoroughly with cold water. The com-
pound so obtained was dried and recrystallized with ethanol.
2.5.1. 3-Diphenylmethyl-6-phenylamino-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazol (5a)
Yield: 80%; m.p.: 153 C. IR (KBr, cm1): 3215 (NH), 2963
(CH), 1624 (C‚N), 706 (CASAC); 1H NMR (DMSO d6) d
(ppm): 5.97 (s, 1H, CH), 7.27–7.56 (m, 15H, ArH), 12.97 (bs,
1H, NH); 13C NMR (DMSO d6), d (ppm): 48.31 (CH),
126.64 (2CHarom), 127.14 (CHarom), 128.31 (2CHarom), 128.94
(4CHarom), 129.12 (4CHarom), 133.24 (2CHarom), 135.46
(2CHarom), 139.19 (CHarom), 141.75 (CHarom), 145.71
(CHarom), 162.34 (CHarom); MS (m/z): 383 (M
+). Anal. Calcd
for C22H17N5S: C, 68.91; H, 4.47; N, 18.26; Found: C, 68.79,
H, 4.19; N, 18.02%.
2.5.2. 6-(4-Chlorophenylamino)-3-diphenylmethyl-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazol (5b)
Yield: 80%; m.p.: 212 C. IR (KBr, cm1): 3230 (NH), 2948
(CH), 1627 (C‚N), 709 (CASAC); 1H NMR (DMSO d6) d
(ppm): 6.02 (s, 1H, CH), 7.14 (d, 2H, J= 6.66 Hz, ArH),
7.29 (d, 2H, J= 6.9 Hz, ArH), 7.39–7.47 (m, 10H, ArH),
12.86 (bs, 1H, NH); 13C NMR (DMSO d6) d (ppm): 48.27
(CH), 126.31 (2CHarom), 127.54 (CHarom), 128.10 (2CHarom),
128.72 (4CHarom), 128.95 (4CHarom), 129.79 (2CHarom),
132.31 (CHarom), 138.98 (2CHarom), 139.54 (CHarom), 148.76
(CHarom), 163.20(CHarom); MS (m/z): 417 (M
+), 419
(M++2). Anal. Calcd for C22H16ClN5S: C, 63.23; H, 3.86;
N, 16.76; Found: C, 68.01, H, 3.67; N, 16.51%.
2.5.3. 3-Diphenylmethyl-6-(4-methylphenylamino)-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole (5c)
Yield: 76%; m.p.: 223 C. IR (KBr, cm1): 3210 (NH), 2958
(CH), 1624 (C‚N), 716 (CASAC); 1H NMR (CDCl3) d
(ppm): 2.31 (s, 3H, CH3), 5.67 (s, 1H, CH), 6.85 (d, 1H,
J= 6.9 Hz, ArH), 7.12 (d, 1H, J= 6.3 Hz, ArH), 7.25–7.32
(m, 12H, ArH), 11.24 (bs, 1H, NH); 13C NMR (CDCl3) d
(ppm): 20.32 (CH), 48.39 (CH), 126.54 (2CHarom), 126.97
(CHarom), 127.89 (2CHarom), 128.32 (4CHarom), 128.43
(4CHarom), 130.23 (2CHarom), 132.45 (CHarom), 139.08
(2CHarom), 139.69 (CHarom), 146.59 (CHarom), 162.24
(CHarom); MS (m/z): 397 (M
+). Anal. Calcd for C23H19N5S:
C, 69.50; H, 4.82; N, 17.62; Found: C, 69.39, H, 5.02; N,
17.49%.
2.5.4. 3-Diphenylmethyl-6-propylamino-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazol (5d)
Yield: 70%; m.p.: 170 C. IR (KBr, cm1): 3205 (NH), 2958
(CH), 1654 (C‚N), 714 (CASAC); 1H NMR (DMSO d6) d(ppm): 0.90 (t, 3H, CH3), 1.56–1.61 (m, 2H, CH2), 3.31 (t,
2H, N-CH2), 5.71 (s, 1H, CH), 7.27–7.33 (m, 10H, ArH),
13.18 (bs, 1H, NH); 13C NMR (DMSO d6) d (ppm): 20.32
(CH), 29.67 (CH), 48.39 (CH), 57.34 (CH), 126.37 (2CHarom),
128.56 (4CHarom), 128.93 (4CHarom), 134.32 (2CHarom), 139.21
(CHarom), 145.19 (CHarom), 163.37 (CHarom); MS (m/z): 349
(M+). Anal. Calcd for C19H19N5S: C, 65.30; H, 5.48; N,
20.04; Found: C, 65.02, H, 5.32; N, 19.91%.3. Biological activity
The synthesized compounds were evaluated for anti-inﬂamma-
tory, analgesic, ulcerogenic and lipid peroxidation activities.
Wistar rats and albino mice used in the present study were
housed and kept in accordance with the Hamdard university
animal care unit, which applies the guidelines and rules laid
down by the committee for the purpose of control and super-
vision of experiments on animals (CPCSEA), Ministry of
social justice and empowerment, Government of India. All
the test compounds and standard drug were administered in
the form of solution (0.5% w/v carboxymethyl cellulose as a
vehicle) by oral route. Each group consists of six animals.
Anti-inﬂammatory activity, hepatotoxic and histopathological
studies of the test compounds were compared with the control.
Analgesic, ulcerogenic and lipid peroxidation activity were
compared with the standard drug i.e., ibuprofen. Data were
analyzed by student’s t test for n= 6.
3.1. Anti-inﬂammatory activity
Anti-inﬂammatory activity was carried out by the carrageenan
induced paw edema test in Wistar albino rats by Winter et al.
(1962) method. The standard drug, ibuprofen and test com-
pounds were given orally (70 mg/kg body weight) as a suspen-
sion using 0.5% w/v carboxymethyl cellulose as a vehicle. One
hour later foot paw edema was induced by injecting 0.1 mL of
1% carrageenan subcutaneously into the planter portion of the
right hind paw of each rat. Initial paw volume was measured
immediately by mercury plethysmometer. The paw volume
was again measured after the time interval of 3 and 4 h. The
percentage inhibition of inﬂammation was calculated for the
standard drug and other test compounds and comparison
was made. The percentage inhibition of inﬂammation was cal-
culated according to the formula, % anti-inﬂammatory activ-
ity = 100 · (1  Vt/Vc) where, Vt and Vc are the volume
edema in test compounds and control groups respectively.
3.2. Analgesic activity
Analgesic activity was evaluated by the tail immersion method
(Adeyemi et al., 2004) using Swiss albino mice (25–30 g) of
either sex selected by the random sampling technique. The
standard drug, ibuprofen and test compounds were adminis-
tered orally (70 mg/kg body weight) as a suspension using
0.5% w/v carboxymethyl cellulose as a vehicle. The lower
5 cm portion of the tail was gently immersed into thermostat-
ically controlled water at 55 ± 0.5 C. The time in seconds for
tail withdrawal from the water was taken as the reaction time
with a cut of time of immersion, set at 10 s for both control as
well as treated groups of animals. The reaction time was
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Scheme 1 Synthetic protocol of the title compounds.
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test compounds and standard drugs.
3.3. Acute ulcerogenicity
Acute ulcerogenesis test was performed according to Cioli
et al. (Cioli et al., 1979) using Wistar rats (180–200 g) of either
sex. The animals were divided into various groups, each group
consisting of 6 rats. All the rats were fasted for 24 h with free
access to water. The control groups of animals were adminis-
tered, 0.5% CMC solution intraperitoneally. One group was
administered with standard drug ibuprofen orally in a dose
of 210 mg/kg once daily for three days. The remaining group
of animals was administered with test compounds through
the same route. The animals were immediately fed and kept
for 17 h after dose administration. After 17 h they were killed
and dissected for the estimation of ulcerogenic activity. The
stomach was dissected out and washed with running water
and opened along the greater curvature and carefully observed
with magnifying glass. For each stomach the mucosal damage
was assessed according to the following scoring system: 0.5:
redness, 1.0: spot ulcers, 1.5: hemorrhagic streak, 2.0: ulcers
>3 but 65, 3.0: ulcers >5. The mean score of each treated
group minus the mean score of the control group was regarded
as severity index of gastric mucosal damage.
3.4. Lipid peroxidation
Lipid peroxidation in the gastric mucosa was determined
according to the method of Ohkawa et al. (Ohkawa et al.,
1979). After the evaluation of the stomach for ulcers the gastric
mucosa of glandular portion was scrapped, weighed (100 mg)
and homogenized in pestle and mortar and homogenate was
prepared in 1.8 mL of ice cold 1.15% KCl solution. The
homogenate was supplemented with 0.2 mL of 8.1% sodium
dodecyl sulfate (SDS), 1.5 mL of acetate buffer and 1.5 mL
of 0.8% thiobarbituric acid (TBA). The mixture was incubated
at 95 C for 60 min on boiling water bath then extracted with a
mixture of n-butanol: pyridine (15:1, v/v; 5 mL) by shaking
vigorously for 1 min and kept in ice for 2 min. Organic layer
of reaction mixture was centrifuged at 3000 rpm for 10 min
and absorbance was measured at 532 nm on a UV spectropho-
tometer. The results were expressed as nmol MDA/100 mg
tissue.
3.5. Hepatotoxic studies
The study was carried out on Wistar albino rats of either sex
weighing 150–200 g. The animals were divided into three
groups of six rats each. Group I was kept as control and
received only vehicle (0.5% w/v solution of CMC in water),
while group II and III received compound 4a and 4c respec-
tively, in 0.5% w/v solution of CMC in water for 15 days.
After the treatment (15 days) blood was obtained from all
the groups of rats by puncturing the retro-orbital plexus.
Blood samples were allowed to clot for 45 min at room temper-
ature and serum was separated by centrifugation at 2500 rpm
for 15 min and analyzed for various biochemical parameters.
Assessment of liver function such as serum glutamate oxaloac-
etate transaminase (SGOT) and serum glutamate pyruvate
transaminase (SGPT) was estimated by a reported method(Reitman and Frankel, 1957). The alkaline phosphatase, total
protein and total albumin were measured according to
reported procedures (King and Armstrong, 1934; Varley,
1988). Histopathological studies were also carried out by the
reported method (Luna, 1968). The rats were sacriﬁced under
light ether anesthesia after 24 h of the last dosage; the liver was
removed and washed with normal saline, and stored in forma-
lin solution. Sections of 5–6 microns thickness were cut,
stained with hematoxylin and eosin, and then studied under
an electron microscope.
3.6. Statistical analysis
Data are expressed as mean ± S.E.M., Student’s t-test was
applied to determine the signiﬁcance of the difference between
the standard group and rats/mice treated with the test com-
pounds. The difference in results was considered signiﬁcant
when P< 0.01.
4. Results and discussion
4.1. Chemistry
The title compounds triazolo-thiadiazole derivatives (4a–j and
5a–d) were synthesized as outlined in Scheme 1. The interme-
diate product 4-amino-5-(diphenylmethyl)-4H-1,2,4-triazole-
3-thiol (3) was prepared following the earlier reported proce-
dure (Reid and Heindel, 1976). Condensation of 3 with substi-
tuted aromatic acids in the presence of phosphorous
oxychloride afforded the corresponding 3-diphenylmethyl-6-
(substituted)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (4a–j),
whereas reaction of 3 with aryl/alkyl isothiocyanates in the
presence of DMF provided 3-diphenylmethyl-6-(substituteda-
mino)-1,2,4-triazolo[3,4-b]-1,3,4 thiadiazoles (5a–d). The ana-
lytical and spectral data of all the synthesized compounds
were in full agreement with the proposed structures. 1H
960 M.W. Akhter et al.NMR spectra of intermediate compound 3 showed a down
ﬁeld broad singlet at d 13.62 whereas the NH2 group appeared
as a singlet at d 5.42 which are D2O exchangeable. The absence
of signals for NH2 and SH protons conﬁrms that the triazole
has been converted into triazolo-thiadiazole derivatives (4a–j
and 5a–d). The elemental analysis results were within ±0.4%
of the theoretical values.
4.2. Pharmacology
The anti-inﬂammatory activity of the synthesized compounds
4a–j and 5a–d was evaluated by the carrageenan induced paw
edema method of Winter et al. The compounds were tested at
an equimolar oral dose relative to 70 mg/kg of ibuprofen.
The percentage inhibition was calculated after 3 and 4 h, and
since it was found to be more after 4 h, this was made the basis
of discussion. The tested compounds showed anti-inﬂamma-
tory activity ranging from 33.46% to 80.13% (Table 1),
whereas standard drug ibuprofen showed 73.23% inhibition
after 4 h. The anti-inﬂammatory activity of triazolo-thiadiazole
derivatives of 4a–j series was in the range of 46.72–80.13%. It
was observed that the triazolo-thiadiazole derivatives having
the 4-chlorophenyl group (4a) at the 6th position showed the
highest activity (80.13%) more than the standard drug ibupro-
fen (73.23%). Furthermore it was noted that the presence of the
2-chlorophenyl group (4b) and the 2,4-dichlorophenyl group
(4c) at the 6th position of the triazolo-thiadiazole ring resulted
in a slight decrease of anti-inﬂammatory activity (74.39% and
76.12% respectively) but still it was found to be more than ibu-
profen (73.23%). It was observed that triazolothiadiazole
derivatives having 2-methylphenyl (4d), 2-bromophenyl (4g),
4-bromophenyl (4h) and 2,4-dichlorophenoxy methyl (4j)
groups also showed good activity viz, 63.65%, 62.67%,
67.47% and 69.45% respectively. Other compounds of the ser-
ies showed moderate to poor activity. The anti-inﬂammatory
activity of 1,2,4-triazolo-thiadiazole derivatives of 5a–d series
was found in the range of 33.46–70.36%. The compound hav-
ing the 4-chlorophenyl amino group showed high anti-inﬂam-
matory activity (70.36%) comparable to standard drug
ibuprofen (73.23%). Replacement of this with phenyl amino
(5a) and the 4-methylphenyl amino group (5c) resulted in a
slight decrease of activity (61.26% and 63.03% respectively).Table 1 Anti-inﬂammatory activity of compounds 4a–j and 5a–d.
Compound Anti-inﬂammatory activity inhibition ± SEM* C
After 3 h After 4 h
4a 77.88 ± 0.91 80.13 ± 0.91b 4
4b 71.18 ± 0.88 74.39 ± 1.15d 4
4c 72.54 ± 0.66 76.13 ± 0.87c 4
4d 58.47 ± 0.89 63.65 ± 0.94a 5
4e 48.21 ± 1.04 50.91 ± 1.05a 5
4f 45.39 ± 1.37 46.72 ± 1.36a 5
4g 58.94 ± 0.60 62.67 ± 1.23a 5
Ibuprofen 70.15 ± 0.80 73.23 ± 1.01 –
# Relative to standard and data were analyzed by student’s t test for n
a p< 0.0001.
b p< 0.001.
c p< 0.05.
d p< 0.5.The compound having the isopropyl amino group (5d) showed
poor activity (33.46%). Thus it was found that the presence of
4-chlorophenyl, 2-chlorophenyl 2,4-dichlorophenyl and
4-chlorophenyl amino groups at the 6th position of the triazol-
o-thiadiazole ring resulted in high anti-inﬂammatory activity.
All these compounds were further tested for their analgesic
activity at the same oral dose as used for the anti-inﬂammatory
activity. The compounds showed analgesic activity ranging
from 40.52% to 79.14% inhibition, whereas standard drug
showed 73.89% (Table 2). The compounds having 4-chloro-
phenyl (4a), 2-chlorophenyl (4b) and 2-methylphenyl (4d)
groups at the 6th position of the triazolo-thiadiazole ring
showed high analgesic activities (74.35%, 79.14% and
74.16% respectively) in comparison to standard drug ibupro-
fen (73.89%). Replacement of these groups by 2-bromophenyl
(4g), 2,4-dicholorophenoxy methyl (4j) and 4-chlorophenyl
amino (5b) groups resulted in a slight decrease of activity
(62.41%, 68.22% and 65.18% respectively). Rest of the com-
pounds showed very low analgesic activities. In general, the
presence of 4-chlorophenyl, 2-chlorophenyl, 2-methylphenyl
groups at the 6th position of the triazolo-thiadiazole ring
resulted in high analgesic activities.
The compounds that exhibited anti-inﬂammatory and anal-
gesic activity higher than 60% were further tested for their
acute ulcerogenic activity. Compounds 4a–d, 4g, 4j and 5a–c
were tested at an equimolar oral dose related to 210 mg/kg ibu-
profen. The tested compounds showed low ulcerogenic activity
ranging from 0.166 ± 0.10 to 0.750 ± 0.17, compared to stan-
dard drug ibuprofen showing high severity index of
0.500 ± 0.00. The maximum reduction in ulcerogenic risk
(0.166 ± 0.10) was found in compound 4c having the
2,4-dichlorophenyl group at the 6th position of the triazolo-
thiadiazole ring. The compounds 4a and 4b showing high
anti-inﬂammatory and analgesic activities and compound 5c
having moderate anti-inﬂammatory and analgesic activities
also showed reduction in severity index (0.250 ± 0.11 and
0.333 ± 0.10 respectively). The compounds 4d, 4g, 4j and
5a–b showed slightly higher ulcerogenic activities in compari-
son to standard drug ibuprofen (Table 2).
Lipid peroxidation refers to the oxidative degradation of
lipids. This process proceeds by free radical chain reaction in
which free radicals steal electrons from the lipid in the cellompound Anti-inﬂammatory activity % inhibition ± SEM#
After 3 h After 4 h
h 64.03 ± 0.88 67.47 ± 0.78b
i 54.05 ± 0.39 58.81 ± 0.82a
j 67.05 ± 0.43 69.45 ± 0.75c
a 57.09 ± 0.54 61.26 ± 0.73a
b 66.26 ± 0.84 70.36 ± 0.65b
c 57.59 ± 0.83 63.03 ± 0.78a
d 28.96 ± 1.09 33.46 ± 0.72a
– –
= 6.
Table 2 Analgesic activity of compounds 4a–j and 5a–d. Ulcerogenic and lipid peroxidation activities of selected compounds.
Compound Analgesic activity# Ulcerogenic activity
(severity index ± SEM)
nmol MDA content ±
SEM/100 mg tissue
Pre-treatment/
normal 0 h (s)
Post-treatment/
after 4 h (s)
% Inhibition
4a 1.51 ± 0.02 2.64 ± 0.07 74.35 ± 1.46d 0.250 ± 0.11* 5.39 ± 0.13*
4b 1.63 ± 0.02 2.93 ± 0.22 79.14 ± 1.82c 0.333 ± 0.10** 5.83 ± 0.16***
4c 2.05 ± 0.01 3.40 ± 0.03 65.67 ± 1.18 0.166 ± 0.10** 3.75 ± 0.08*
4d 1.27 ± 0.01 2.22 ± 0.02 74.16 ± 0.96a 0.666 ± 0.10** 5.60 ± 0.14**
4e 1.63 ± 0.01 2.52 ± 0.04 54.23 ± 1.98a – –
4f 1.51 ± 0.01 2.39 ± 0.00 57.85 ± 1.03a – –
4g 1.36 ± 0.01 2.20 ± 0.01 62.41 ± 1.31b 0.750 ± 0.17** 5.35 ± 0.11*
4h 1.76 ± 0.03 2.65 ± 0.01 50.99 ± 1.50a – –
4i 1.59 ± 0.02 2.47 ± 0.01 55.04 ± 1.17a – –
4j 1.91 ± 0.01 3.21 ± 0.01 68.22 ± 0.85c 0.583 ± 0.08** 5.10 ± 0.19*
5a 1.74 ± 0.15 2.70 ± 0.01 55.70 ± 1.09a 0.750 ± 0.17** 5.98 ± 0.19****
5b 1.49 ± 0.01 2.47 ± 0.01 65.18 ± 1.12b 0.750 ± 0.11** 5.32 ± 0.17*
5c 1.38 ± 0.01 2.16 ± 0.01 56.33 ± 1.55a 0.250 ± 0.11** 4.48 ± 0.22*
5d 1.60 ± 0.00 2.24 ± 0.01 40.52 ± 0.58a – –
Control – – – 0.000 ± 0.00 3.31 ± 0.06
Ibuprofen 1.36 ± 0.00 2.37 ± 0.01 73.89 ± 1.35 0.500 ± 0.00 6.60 ± 0.11
Relative to standard and data were analyzed by student’s t test for n= 6.
# ap< 0.0001, bp< 0.001, cp< 0.01, dp< 0.05, ep< 0.5.
 *p< 0.05, **p< 0.5.
 *p< 0.0001, **p< 0.001, ***p< 0.01, ****p< 0.05.
Synthesis of 3-diphenylmethyl-6-substituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles 961membrane and consequently damage the cell. It most often
affects polyunsaturated fatty acids forming malondialdehyde
(MDA). The colorimetric reaction of thiobarbituric acid
(TBA) with MDA, a secondary product of lipid peroxidation
(LPO) has been widely adopted as a sensitive assay method
for measuring LPO in animal tissues. It is used as an index
of the extent to which LPO has progressed. Since the assay
procedure estimates the amount of TBA reactive substances
e.g., MDA, it is also referred to as TBARS (Thiobarbituric
Acid Reactive Substance) test. It has been reported that the
compounds showing less ulcerogenic activity also showed
reduced malondialdehyde (MDA) content, a by-product of
lipid peroxidation (Phole et al., 2001). Therefore, an attempt
was made to correlate the decrease in ulcerogenic activity of
the compounds with that of lipid peroxidation. All the com-
pounds screened for ulcerogenic activity were also analyzed
for lipid peroxidation. The lipid peroxidation was measured
as nanomoles of malondialdehyde (MDA)/100 mg of gastric
mucosa tissue. Ibuprofen exhibited high lipid peroxidation
6.60 ± 0.11, whereas the control group showed 3.31 ± 0.06.
It was found that all the triazolo-thiadiazole derivatives show-
ing less ulcerogenic activity also showed reduction in lipid per-Table 3 Effect of compounds 4a and 4c on serum enzymes, total p
Compound SGOT units/ml# SGPT units/ml# Alkalin
Control 161.04 ± 2.29 51.96 ± 0.82 45.62 ±
Ibuprofen 165.57 ± 2.32e 53.14 ± 1.53 47.72 ±
4a 173.71 ± 3.13c 55.39 ± 1.18d 51.51 ±
4c 135.71 ± 2.80e 41.44 ± 1.38a 43.63 ±
# Relative to control and data were analyzed by student’s t test for n=
a p< 0.0001.
b p< 0.001.
c p< 0.01.
d p< 0.05.
e p< 0.5.oxidation (Table 2). Thus these studies showed that the
synthesized compounds have inhibited the induction of gastric
mucosal ulcer and the results further suggested that their pro-
tective effect might be related to the inhibition of lipid
peroxidation in the gastric mucosa.
The compounds 4a and 4c, triazolo-thiadiazole derivatives
of diphenylacetic acid showing potent anti-inﬂammatory and
analgesic activities with reduced ulcerogenicity and lipid per-
oxidation, were further studied for their hepatotoxic effect.
Both compounds were studied for their effect on biochemical
parameters (serum enzyme, total protein and total albumin).
Liver histopathological testing of these compounds was also
carried out. As shown in Table 3, activities of liver enzyme
SGOT, SGPT, alkaline phosphatase, total protein and total
albumin were almost identical with ibuprofen value, except
for compound 4c whose SGOT and SGPT level was found
to be reduced. The histopathological studies of the liver sample
of standard drug ibuprofen showed evident centrizonal
sinusoidal dilation in comparison to control. The compound
4a when tested for their histopathological studies showed cen-
trizonal sinusoidal dilation equivalent to ibuprofen whereas
compound 4c showed very mild sinusoidal dilation (Fig. 1).roteins and total albumin.
e phosphatase# Total protein g/dl# Total albumin g/dl#
0.72 1.83 ± 0.00 1.74 ± 0.01
1.30e 1.90 ± 0.01c 1.68 ± 0.01d
0.80b 2.01 ± 0.02a 1.90 ± 0.02a
1.53e 1.78 ± 0.01c 1.63 ± 0.01b
6.
Control:  normal arrangement of 
hepatocytes in the centrizonal area (400X)
Ibuprofen: Showing evident centrizonal 
sinusoidal dilatation (400X) 
Compound 4a: Showing evident
centrizonal sinusoidal dilatation (400X)
Compound 4c: showing a very mild 
sinusoidal dilatation is seen (400X) 
Figure 1 Histopthalogical studies of the liver.
962 M.W. Akhter et al.This indicates the safety of compound 4c with respect to stan-
dard drug.5. Conclusion
In summary, various triazolo-thiadiazole derivatives of diphe-
nyl acetic acid were synthesized and screened for anti-inﬂam-
matory, analgesic, ulcerogenic and lipid peroxidation
activities. It was observed that three cyclized compounds 4a,
4b and 4c were found to have anti-inﬂammatory properties
more than or comparable to their standard reference drug ibu-
profen. When these compounds were subjected to analgesic
activity by the tail immersion method in mice, they exhibited
moderate to good activity. These compounds were also tested
for ulcerogenic activity and lipid peroxidation, and showed
superior GI safety proﬁle along with reduction in lipid perox-
idation as compared with standard drug ibuprofen. From
these studies, compounds 4a, 6-(4-chlorophenyl)-3-(diphenyl-
methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole and 4c, 6-(2,
4-dichlorophenyl)-3-(diphenylmethyl)-1,2,4-triazolo[3,4-b]-1,3,
4-thiadiazole have emerged as the lead compounds, which
showed the most prominent and consistent activity with max-
imum reduction in gastrointestinal toxicity and minimum lipid
peroxidation. Thus the series provided new opportunities for
possible modiﬁcation of pharmacophoric requirements and
future exploitation.
Acknowledgements
The authors are grateful to University Grants Commission
(UGC) New Delhi for ﬁnancial support. Authors are also
thankful to Central Instrumentation Facility (CIF) Facultyof Pharmacy for spectral analysis of compounds and to Dr.
Ambrish Kumar Tiwari, In-charge animal house, Jamia Ham-
dard, for providing animals. The authors are also thankful to
Dr. A. Mukharjee, MD, Department of Pathology, All India
Institute of Medical Sciences (AIIMS), New Delhi, for carry-
ing out histopathological studies.References
Adeyemi, O.O., Okpo, O.S., Okpaka, O., 2004. The analgesic effect of
the methanolic extract of Acanthus montanus. J. Ethnopharmacol.
90, 45–48.
Allison, M.C., Howatson, A.G., Torrance, C.J., Lee, F.D., Russell,
R.I.G., 1992. Gastrointestinal damage associated with the use of
nonsteroidal anti-inﬂammatory drugs. N. Engl. J. Med. 327, 749–
754.
Amir, M., Kumar, S., 2004. Synthesis and anti-inﬂammatory, analge-
sic, ulcerogenic and lipid peroxidation activities of some new 2-
[(2,6-dichloroanilino) phenyl]acetic acid derivatives. Eur. J. Med.
Chem. 39, 535–545.
Amir, M., Kumar, S., 2005. Synthesis of some new 2- (2-ﬂuoro-4-
biphenyl-yl) propionic acid derivatives as potential anti-inﬂamma-
tory agents. Pharmazie 60, 175–180.
Amir, M., Kumar, H., Javed, S.A., 2007. Synthesis and pharmaco-
logical evaluation of condensed heterocyclic 6-substituted-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole derivatives of naproxen. Bioorg.
Med. Chem. Lett. 17, 4504–4508.
Amir, M., Kumar, H., Khan, S.A., 2008. Synthesis and pharmaco-
logical evaluation of pyrazoline derivatives as new anti-inﬂamma-
tory and analgesic agents. Bioorg. Med. Chem. Lett. 18, 918–922.
Cioli, V., Putzolu, S., Rossi, V., Barcellona, S.P., Corradino, C., 1979.
The role of direct tissue contact in the production of gastrointes-
tinal ulcers by anti-inﬂammatory drugs in rats. Toxicol. Appl.
Pharmacol. 50, 283–289.
Synthesis of 3-diphenylmethyl-6-substituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles 963Dogne, J.M., Supuran, C.T., Pratico, D., 2005. Adverse cardiovascular
effects of the coxibs. J. Med. Chem. 48, 2251–2257.
Kalgutkar, A.S., Marnett, A.B., Crews, B.C., Remmel, R.P., Marnett,
J.L., 2000. Ester and amide derivatives of the non steroidal anti-
inﬂammatory drug indomethacin as selective cyclooxygenase-2
inhibitors. J. Med. Chem. 43, 2860–2870.
Karthikeyan, M.S., Holla, B.S., Kulkuraya, B., Kumari, N.S., 2007.
Biological studies of some 2,4-dichloro-5-ﬂouorophenyl containing
triazolo-thiadiazoles. Monatsh. Chem. 138, 1309–1316.
Karegouder, P., Prasad, D.J., Ashok, M., Mahalinga, M., Poojary, B.,
Holla, B.S., 2008. Synthesis, antimicrobial and anti-inﬂammatory
activities of some 1,2,4-triazolo[3,4-b][1,3,4]-thiadazole and 1,2,4-
triazolo[3,4-b][1,3,4]-thiadiazoles bearing trichlorophenyl moiety.
Eur. J. Med. Chem. 43, 808–815.
King, E.J., Armstrong, A.R., 1934. A convenient method for deter-
mining serum and bile phosphate activity. Can. Med. Assoc. J. 31,
376–381.
Kucukguzel, S.G., Kucukguzel, I., Tatar, E., Rollas, S., Sahin, F.,
Gulluce, M., Clercq, E.D., Kabasakal, L., 2007. Synthesis of some
novel heterocyclic compounds derived from diﬂunisalhydrazide as
potential anti-infective and anti-inﬂammatory agents. Eur. J. Med.
Chem. 4, 893–901.
Luna, L.G., 1968. Manual of Histological Staining Methods of the
Armed Forces Institute of Pathology, 3rd ed. Mc-Graw-Hill, New
York, pp. 567–568.
Mathew, V., Keshavayya, J., Vaidya, V.P., 2006. Heterocyclic system
containing bridgehead nitrogen atom: synthesis and pharmacolog-
ical activities of some substituted 1,2,4-triazolo[3,4-b]-1,3,4-thi-
adiazoles. Eur. J. Med. Chem. 41, 1048–1058.
Mathew, V., Keshavayya, J., Vaidya, V.P., 2007. Studies on synthesis
and pharmacological activities of some substituted-1,2,4-triazol-
o[3,4-b]-1,3,4-thiadiazoles. Eur. J. Med. Chem. 42, 823–840.
Metwally, K.A., Yasheen, S.H., Lashine, E.S.M., Fayomi, H.M.E.,
Sadek, M.M.E., 2007. Non-carboxylic analogues of arylpropionic
acids: synthesis, anti-inﬂammatory activity and ulcerogenic poten-
tial. Eur. J. Med. Chem. 42, 152–160.
Ohkawa, H., Ohishi, M., Yagi, K., 1979. Assay for lipid peroxides in
animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95,
351–358.
Phole, T., Brzozowski, T., Becker, J.C., Vander Voort, I.R., Mark-
man, A., Konturek, S.J., Moniczewski, A., Domschke, W.,Konturek, 2001. Role of reactive oxygen metabolites in aspirin-
induced gastric damage in humans: gastroprotection by vitamin C.
Aliment. Pharmacol. Ther. 5, 677–687.
Reid, J.R., Heindel, N.D., 1976. Improved syntheses of 5-substituted-
4-amino-3-mercapto-(4H)-1,2,4-triazoles. J. Heterocycl. Chem. 13,
925–926.
Reitman, S., Frankel, S., 1957. A colorimetric method for the
determination of serum glutamic oxaloacetic and glutamic pyruvic
transaminases. Am. J. Clin. Pathol. 28, 56–63.
Schenone, S., Brullo, C., Bruno, O., Bondavalli, F., Ranise, A.,
Filippeli, W., Rinaldi, B., Capuano, A., Falcone, G., 2006. New
1,3,4-thiadiazole derivatives endowed with analgesic and anti-
inﬂammatory activities. Bioorg. Med. Chem. 14, 1698–1705.
Swamy, S.N., Priya, B.S., Prabhuswamy, B., Doerswamy, B.H.,
Prasad, J.S., Rangappa, K.S., 2006. Synthesis of pharmacologically
important condensed heterocyclic 4,6-substituted-1,2,4-triazolo-
thiadiazole derivatives as antimicrobials. Eur. J. Med. Chem. 41,
531–538.
Tally, J.J., Bertenshaw, R.S., Brown, D.L., Carter, J.S., Graneto, M.J.,
Kellogg, M.S., Kobolt, C.M., Yuan, J., Zhang, Y.Y., Seibert, K.,
2000. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]pro-
panamide, sodium salt, Parecoxib sodium: a potent and selective
inhibitor of COX-2 for parenteral administration. J. Med. Chem.
43, 1661–1663.
Tozkoparan, B., Kupeli, E., Yesilada, E., Ertan, M., 2007. Preparation
of 5-aryl-3-alkylthio-l,2,4-triazoles and corresponding sulfones with
anti-inﬂammatory analgesic activity. Bioorg. Med. Chem. 15,
1808–1814.
Varley, H., 1988. Practical Clinical Biochemistry, 1st ed. CBS
Publishers and Distributors, New Delhi, pp. 236-238.
Warner, T.D., Giuliano, F., Vaynovic, I., Bukasa, A., Mitchell, J.A.,
Vave, J.R., 1999. Nonsteroid drug selectivities for cyclo-oxygenase-
1 rather than cyclo-oxygenase-2 are associated with human
gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad.
Sci. USA 96, 7563–7568.
Winter, C., Risley, E.A., Nuss, G.W., Winter, C.A., Risley, E.A.,
Nuss, G.W., 1962. Carrageenan-induced edema in hind paws of the
rat as an assay for anti-inﬂammatory drugs. Proc. Soc. Exp. Biol.
Med. 111, 544–547.
